Alzheimer's & Dementia·13 AugLong-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension studyTrial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecIntegrating Plasma pTau‐217 and Aβ42/Aβ40 Ratio for Accurate Non‐Invasive Prediction of Brain Amyloid AccumulationStudy in peopleBiomarkersPaper